Drug Safety and Effectiveness Network, Canada
16
0
0
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 16 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)
Role: collaborator
Domperidone and Risk of Serious Cardiac Events in Postpartum Women
Role: collaborator
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events
Role: collaborator
Hydrochlorothiazide and Risk of Skin Cancer
Role: collaborator
Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes
Role: collaborator
Domperidone and Risk of Sudden Cardiac Death
Role: collaborator
Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)
Role: collaborator
Direct Oral Anticoagulants and Venous Thromboembolism
Role: collaborator
Incretin-based Drugs and Acute Pancreatitis
Role: collaborator
Incretin-based Drugs and the Risk of Heart Failure
Role: collaborator
Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury
Role: collaborator
High Potency Statins and the Risk of Diabetes
Role: collaborator
High Potency Statins and Acute Kidney Injury
Role: collaborator
Incretin-based Drugs and Pancreatic Cancer
Role: collaborator
Antipsychotics and Risk of Hyperglycemic Emergencies
Role: collaborator
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
Role: collaborator
All 16 trials loaded